COMPANY PROFILE / #1153
Frontier Medicines
San Francisco, CAVenture Capital-Backed
OVERVIEW
Developer of a chemoproteomics platform designed to accelerate the development of medicines. The company's platform integrates computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling healthcare professionals to provide medicines to patients that redefine the course of debilitating diseases.
已融资255.50
最新估值430.00
员工数77
成立年份2018
公司概况
- Companies
- Frontier Medicines
- Description
- Developer of a chemoproteomics platform designed to accelerate the development of medicines. The company's platform integrates computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling healthcare professionals to provide medicines to patients that redefine the course of debilitating diseases.
- Website
- www.frontiermeds.com
- HQ Location
- San Francisco, CA
- Year Founded
- 2018
- Keywords
- bioinformatics product, biopharma company, biopharmaceutical company, chemoproteomics platform, development platform, drug development company, drug discovery firm, medicine developer
- Competitors
- Kymera Therapeutics, Arvinas, C4 Therapeutics, Dendreon, Nurix Therapeutics
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 255.50
- First Financing Date
- 01-Jan-2018
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 26-Feb-2024
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 100.00
- Last Financing Valuation
- 430.00
- Last Financing Status
- Completed
- Last Known Valuation
- 430.00
- Last Known Valuation Date
- 26-Feb-2024
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 336.47
- Valuation Estimate Growth Rate
- -21.75%
- Active Investors
- ArrowMark Partners, DCVC Bio, Deep Track Capital, Deerfield Management, Driehaus Capital Management, Droia Ventures, Johnson & Johnson Innovation - JLABS, Lakefront Biotherapeutics, MPM BioImpact, Pandect / Berkeley Catalyst Fund, RA Capital Management, Sphera Funds Management, University of California, Berkeley, Woodline Partners
- # Active Investors
- 14
- Acquirers
- —
团队与联系人
- Employees
- 77
- Employee Growth %
- -7.23%
- Employee History
- 2026: 77, 2025: 83, 2024: 111, 2023: 119, 2022: 90, 2021: 56, 2020: 33 E, 2019: 10
- Primary Contact
- Daniel Nomura
- Primary Contact Title
- Co-Founder & Advisor
- Primary Contact Email
- daniel.nomura@frontiermeds.com
- Primary Contact Phone
- +1 (650) 457-1005
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- -0.04%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 13
- Size Multiple
- 8.12x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 90
- Majestic Referring Domains
- 260
- SimilarWeb Unique Visitors
- 403
- SimilarWeb Unique Visitors Change
- -69
- SimilarWeb Growth Rate
- 0.00%
- SimilarWeb Growth Rate Percentile
- 9
- Success Probability Over Time – 1 Year
- 27%
- Success Probability Over Time – 3 Year
- 46%
- Success Probability Over Time – 5 Year
- 56%
记录来源：public.companies · 原始序号 #1153 · 所有字段均按数据库原值展示。